Zhejiang Huahai Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600521.SS

Zhejiang Huahai Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 1.17 B

Zhejiang Huahai Pharmaceutical Co., Ltd. Revenue is USD 1.17 B for the year ending December 31, 2023, a -2.30% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Zhejiang Huahai Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 1.20 B, a 14.56% change year over year.
Zhejiang Huahai Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 1.05 B, a 5.24% change year over year.
Zhejiang Huahai Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 993.53 M, a 28.41% change year over year.
Zhejiang Huahai Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 773.73 M, a 4.45% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 600521.SS

Zhejiang Huahai Pharmaceutical Co., Ltd.

CEO	Mr. Bao Hua Chen
IPO Date	March 4, 2003
Location	China
Headquarters	Xunqiao
Employees	8,221
Sector	Health Care
Industries Pharmaceuticals

Description

Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also engages in packaging components business, such as high-density polyethylene bottles and polypropylene caps. In addition, the company provides contract manufacturing and other services. Further, it is involved in import and export trade services. Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.

Key trends

Past 5 years